Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Written by Customer Service on . Posted in Public Companies.

WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.

Jefferies Global Healthcare Conference 2024:
On Thursday, June 6th, at 1:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. A live webcast of the fireside chat can be accessed here.

Goldman Sachs 45th Annual Global Healthcare Conference:
On Wednesday, June 12th, at 10:40 a.m. ET, Dr. Vaddi will provide a corporate presentation. The live webcast of the presentation can be accessed here.

For more information, visit Prelude’s website under Events and Presentations. All webcast recordings will be archived and available on the Company’s website for 90 days.

About Prelude Therapeutics 

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes three candidates currently in clinical development: an IV administered, potent and highly selective SMARCA2 degrader, PRT3789, a potent and highly selective CDK9 inhibitor, PRT2527, and a next generation CDK4/6 inhibitor, PRT3645. Prelude is also developing a potent, highly selective, orally bioavailable SMARCA2 degrader, PRT7732. The company is also collaborating with AbCellera to jointly discover, develop and commercialize up to five precision, next generation antibody drug conjugate (ADC) products combining AbCellera’s antibody discovery and development engine with Prelude’s expertise in medicinal chemistry and drug development. For more information, visit our website and follow us on LinkedIn.

Investor Contact:
Robert Doody
Senior Vice President, Investor Relations
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com

Media Contact:
Helen Shik
Shik Communications
617.510.4373
Helen@ShikCommunications.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.